Latest news with #EricChen
Forbes
5 days ago
- Business
- Forbes
AI PCs Will Dominate By 2027, Says Asus Executive
So-called AI PCs will account for more than half of PC shipments by 2027, according to a senior Asus executive. Demand for AI PCs – which ship with a neural processing unit (NPU) to assist with AI tasks – has been relatively modest so far. The market share of AI PCs is 'still single digit', Eric Chen, Asus's senior corporate vice president told me in a briefing to coincide with last week's Computex trade show. 'It's not that big,' he admitted. However, he said that growth over the next couple of years will mean that by 2027 'over 50%' of total PC shipments will be AI PCs. Asus's predictions are roughly in line with that of major analysts such as Gartner, IDC and Canalys, all of which have predicted steep growth in AI-capable PCs over the next few years. The big challenge for PC makers is giving businesses and consumers a solid reason to pay a premium for an AI PC. Popular AI services such as ChatGPT, Google Gemini or Anthropic's Claude are cloud based and don't directly benefit from the presence of an NPU. Meanwhile, Microsoft has struggled to deliver compelling AI features in Windows, with the highly controversial and much delayed Recall feature only arriving on Copilot+ machines at the end of last month. Microsoft was forced to pull an early test version of the all-seeing Recall after serious security flaws were discovered by testers, which have now been fixed. Chen said 'the big bottleneck" right now is that users don't fully understand how AI can help them. He gave an example of how Asus is deploying AI within its own business to check the paperwork that comes with business transactions. Previously that task was done by hand, but now the company is using AI to process the paperwork. 'They used to spend 200 hours to do the checks,' said Chen. 'Now, three hours. That's a big, big difference.' It's those kinds of tasks involving sensitive customer data that companies might not want uploaded to cloud services that will really take advantage of the local processing power offered by AI PCs, Chen claimed. 'A lot of companies and people, they don't want their data to upload to the cloud,' he said. Although Asus has been developing a suite of its own applications, such as Muse Tree, which offers AI image generation without relying on expensive, resource-hungry cloud services, Chen concedes that professionals will still turn to the cloud when they need the optimal quality. He said that 'local is already good enough" for many lightweight tasks, however, and that cloud AI services will eventually start tapping the power available to AI PCs. 'The cloud and the local, they will work together. That is one of the trends that will happen,' Chen added. AI PCs may well hold more appeal to businesses than consumers right now, and that's perhaps one of the reasons that Asus has decided to ramp up its commercial offering, pitting the company into even stronger competition with rivals such as Dell and Lenovo. 'In the past 35 years, we are more focused on the consumer PC business,' said Chen. 'In the coming years, Asus will develop our commercial business as well.' IDC's figures for 2024 worldwide PC shipments put Asus in fifth position, with a market share of around 7%. But Chen said the company had 'very aggressive' plans to attack the commercial market in a bid to close the gap to market leader Lenovo, which shipped more than three times as many PCs as Asus did in 2024, according to IDC's figures.
Business Mayor
24-05-2025
- Business
- Business Mayor
Injective leads AI token surge with 12% rise – Is $17 possible for INJ?
INJ, on the daily time frame, completed a clean inverse heads and shoulders pattern. Injective's $2B annualized trading volume for iAssets could accelerate the onboarding of tokenized stocks & RWAs. The altcoins are back to performance with most AI tokens, including Injective [INJ] and Artificial Superintelligence Alliance [FET] among others, gaining ground after potentially finishing the correction. Price analysis and market sentiment Injective completed an inverse head and shoulders pattern on the daily timeframe, and a breakout verified at the $11.16 level. Once it settled above the neckline, INJ made a big move up, rising 12% in just a day. The volume followed with an 87% daily rise. The price crossed both the 50-day EMA at $10.81 and the 100-day SMA at $11.16 and continued rising, showing momentum was bullish, and the trend could keep going. As trading increased on the breakout, it proved the structure was strong after the crossover. Should Injective's price remain supported at the neckline and by both averages, it could continue moving upwards and test the $16.50 to $17.00 level in the short run. Source: TradingView However, a failure to hold above $15.00 may trigger a slide back to $12.80—or, in a deeper retracement, to the 100-day SMA near $11.16. If that level breaks, the bullish setup would likely invalidate, opening room for downside risk. At the same time, statistics showed over 95% of respondents thought JasmyCoin [JASMY] and Injective were poised for growth. Due to the strong investor conviction, INJ was probably doing well following ongoing media appearances, keeping the project in the limelight. Read More How FTX can impact ETH's future price movements There were also sentiments of 94.90%, 94.70% and 93.40% for Jupiter [JUP], Virtuals Protocol [VIRTUAL] and Cardano [ADA], respectively. With both INJ's high ratings and the momentum, there was a real chance the protocol's ecosystem could grow over the long term. Injective's annualized volume for iAssets The media presence also helped. Ongoing exposure—including Eric Chen's recent appearance on CNBC—keeps INJ in the spotlight, boosting investor confidence. On top of price action, Injective recently hit a $2 billion annualized trading volume for its tokenized assets (iAssets). These include tokenized stocks and real-world assets (RWAs), key growth areas that are drawing both institutional and retail interest. Source: X While publicity from the DAO can lift the project's credibility, INJ's price responsiveness would rely on continuous platform implementation and changes in the market. An increase in institutional interest could bring upside movement to INJ. However, future growth needed the network to attract users and for the overall market to improve.
CNBC
21-05-2025
- Business
- CNBC
Bitcoin falls after hitting new record high of $109,500: CNBC Crypto World
On today's episode of CNBC Crypto World, Bitcoin sets a new record price. Plus, the SEC files charges against the crypto firm Unicoin and its top executives for alleged fraud. And, Eric Chen, co-founder of Injective, reacts to bitcoin's new record and provides his outlook for the cryptocurrency.
CNBC
09-05-2025
- Business
- CNBC
Bitcoin holds above $100,000 while ether rockets to its best week since 2021
Cryptocurrencies extended their rally to end the week, with bitcoin holding steady above the $100,000 level while ether rallied to its best week since 2021. The price of bitcoin was higher by 2% at $103,249.99 on Friday, according to Coin Metrics. Earlier, it rose as high as $104,324.65, its highest level since Jan. 31. For the week, bitcoin is up more than 6% and on pace for its fourth positive week in a row – and first four-week win streak since November. "This move above $100,000 should be viewed as more than mere euphoria, but rather as evidence of a flows-driven shift," said Gadi Chait, head of investment at bitcoin-native Xapo Bank. "Whales have been accumulating on-chain, ETF demand continues to set new records, and investors seek 'neutral' assets amid a tariff-shadowed macro environment. Meanwhile, the announcement of a U.S.–U.K. 'mini-deal' and hints of tariff relief with China have reduced overall risk aversion, lifting equities, oil, and, notably, Bitcoin." The risk-on sentiment bled into altcoins, or cryptocurrencies that aren't bitcoin, most of which have struggled to keep pace with bitcoin's gains this year. Ether, one of the biggest stragglers, jumped 10%, bringing its two-day gain up to 29%. A 6% increase in the token tied to Solana brought its two-day gain to 16%. This week the Ethereum network also completed its latest technology upgrade, dubbed Pectra, which enables lower network fees, streamlined ether staking and support for smart wallets. Ether is up 25% week to date and on pace for its best week since May 2021. The Solana token has added 14.3% this week, which is on track to be its best week since January. Year to date, however, ether and other major altcoins – with the exception of XRP – are still deep in the red compared to bitcoin. While the flagship crypto is up 10%, ether and the Solana token are down 31% and 12%, respectively. Bitcoin's market structure changed after the introduction of spot bitcoin ETFs in 2024, with demand now coming from retirement accounts, macro funds, and corporate bonds such as Strategy. By contrast, altcoins still rely on crypto-native, risk-on capital, which hasn't shown significant growth alongside the greater tech sector due to the current interest rate environment, according to Eric Chen, Co-Founder of Injective. Bitcoin is likely to keep outperforming until broader capital flows into altcoins, he added, given their steady supply and lack of a structural buyer base, which are likely to take prices lower until they attract speculative interest. "For us, there remains one singular strategy for crypto investors: stick to BTC until risk on headwinds dissipate," Wolfe Research analyst Read Harvey said in a note this week. "The coin is one of just two in our basket positive on the year and it continues to dominate the rest of the space on a relative basis. The question now shifts towards if it can maintain recent outperformance vs. equities, or if Gold was right all along."
Los Angeles Times
19-04-2025
- Health
- Los Angeles Times
Advancing Medical Education and Global Collaboration
Kaohsiung Medical University (KMU) and its affiliated Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) stand at the heart of Southern Taiwan's healthcare and medical education ecosystem. As the only one of Taiwan's original four accredited medical centers located outside Taipei, KMUH plays a crucial role in providing specialized care, training future doctors and driving medical innovation for the region. KMUH has secured three consecutive Joint Commission International (JCI) accreditations, in 2016, 2019, and 2022, placing it among a select group of institutions maintaining continuous global certification. According to Eric Chen, Chairman of the Board, these accreditations are only the foundation. 'JCI is not a trophy – it's a baseline. What truly matters is how we build on that foundation to enhance education, research, and care.' KMU integrates clinical training at KMUH directly into its medical curriculum, combining academic rigor with practical immersion. Its commitment to global partnerships is evident in its clinical rotation programs, which regularly host students from Stanford University and Harvard Medical School. 'These rotations expose students to disease patterns rarely seen in the United States, such as tuberculosis,' says Chen. 'At the same time, they experience a fully digital healthcare system, something that sets Taiwan apart internationally.' This global exposure does not end at student exchanges. KMU actively collaborates with U.S. medical centers, pharmaceutical companies, and biopharmaceutical firms, positioning itself as a clinical trial hub for companies seeking to expand into the Asian market. 'Our medical records system is fully digital and physician notes are written in English, which simplifies data sharing for international research,' Chen explains. 'We currently have 20 to 30 active AI projects, many of which directly support clinical research workflows.' Taiwan's global leadership in semiconductors and ICT creates natural synergies for KMU, allowing the university to integrate advanced hardware, AI algorithms, and clinical data into a cohesive research environment. 'AI and technology are critical, but they must enhance human care, not replace it,' says Chen. 'Every AI system we deploy includes manual oversight, ensuring that technology serves the doctor-patient relationship, not the other way around.' With its fully digital infrastructure and its data-sharing culture, KMU offers pharmaceutical companies and research partners a streamlined path for conducting large-scale clinical trials in Taiwan, while simultaneously advancing its own AI research agenda. Kaohsiung Medical University is firmly positioned as a leader in advancing public health and sustainable development on a national scale. In the 2024 THE World University Rankings, KMU achieved the highest ranking in Taiwan for SDG 3 (Good Health and Well-being) and SDG 5 (Gender Equality), with an exceptional global ranking of sixth in SDG 3. This achievement highlights KMU's outstanding contributions to public health, which extend far beyond local initiatives. The university's commitment to SDGs is a key part of its 'Leading the Nation' policy, which drives its influence on national healthcare strategies and sets a global example for sustainable healthcare practices. KMU is not only a leader in Taiwan but is actively shaping public health innovations that can have a global impact. Taiwan's declining birthrate – with over 20% of the population now over 65 – is driving KMU to actively recruit international students, particularly into its English-taught postgraduate programs aimed at students from the U.S., Canada, and Europe. 'Taiwan offers world-class medical education at a fraction of U.S. tuition,' Chen explains. 'If we can attract North American students for two years of medical school here, and then support them to complete residency in their home countries, we create a new generation of doctors with deep ties to Taiwan.' KMU's international strategy balances collaborations with elite institutions in the U.S., Japan, and Europe with capacity-building partnerships in Southeast Asia and other emerging regions. This dual approach reflects both KMU's strategic ambitions and Taiwan's historical commitment to global health cooperation. 'Taiwan's medical sector owes much to early Western medical missionaries, and now it's our turn to pay that forward,' says Chen. 'We want KMU to link upward to global leaders like Stanford while simultaneously lifting up promising institutions in Vietnam, Indonesia and beyond.' Looking ahead, KMU and KMUH actively invite pharmaceutical companies, technology innovators, and academic institutions to explore collaborative opportunities in Kaohsiung. Whether in clinical trials, AI innovation, sustainable hospital design, or international medical education, KMU aims to become a preferred partner for global healthcare innovation. 'Kaohsiung offers something few places in the world can match – a globally connected medical university, an accredited teaching hospital and direct access to the technological powerhouse that is Taiwan,' concludes Chen. 'For any partner looking to bridge Western innovation with Asia's healthcare future, Kaohsiung is ready.'
